Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey William Clark, M.D.

Co-Author

This page shows the publications co-authored by Jeffrey Clark and Lawrence Blaszkowsky.
Connection Strength

2.645
  1. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
    View in: PubMed
    Score: 0.122
  2. Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discov. 2022 Mar 23.
    View in: PubMed
    Score: 0.062
  3. Positron Emission Tomography/Magnetic Resonance Imaging Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis. Ann Surg. 2022 Feb 17.
    View in: PubMed
    Score: 0.062
  4. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021 Nov; 2(11):1124-1135.
    View in: PubMed
    Score: 0.061
  5. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer. 2021 09; 125(7):975-982.
    View in: PubMed
    Score: 0.059
  6. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncol Pract. 2021 12; 17(12):e1846-e1855.
    View in: PubMed
    Score: 0.059
  7. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 10 15; 27(20):5586-5594.
    View in: PubMed
    Score: 0.058
  8. The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. JACC CardioOncol. 2021 Mar; 3(1):101-109.
    View in: PubMed
    Score: 0.058
  9. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.057
  10. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol. 2021 06; 23(3):456-466.
    View in: PubMed
    Score: 0.057
  11. Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer. 2021 02 15; 127(4):619-627.
    View in: PubMed
    Score: 0.057
  12. Improving staging of rectal cancer in the pelvis: the role of PET/MRI. Eur J Nucl Med Mol Imaging. 2021 04; 48(4):1235-1245.
    View in: PubMed
    Score: 0.056
  13. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700.
    View in: PubMed
    Score: 0.056
  14. Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2020 12; 25(12):1015-1022.
    View in: PubMed
    Score: 0.056
  15. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
    View in: PubMed
    Score: 0.053
  16. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949.
    View in: PubMed
    Score: 0.053
  17. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Ann Surg Oncol. 2020 May; 27(5):1400-1406.
    View in: PubMed
    Score: 0.053
  18. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421.
    View in: PubMed
    Score: 0.052
  19. Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2019 Oct; 46(11):2260-2269.
    View in: PubMed
    Score: 0.052
  20. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.051
  21. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):90-95.
    View in: PubMed
    Score: 0.051
  22. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
    View in: PubMed
    Score: 0.051
  23. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.
    View in: PubMed
    Score: 0.050
  24. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):64-72.
    View in: PubMed
    Score: 0.050
  25. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 07 01; 4(7):963-969.
    View in: PubMed
    Score: 0.048
  26. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661.
    View in: PubMed
    Score: 0.048
  27. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol. 2018 06; 41(6):607-612.
    View in: PubMed
    Score: 0.048
  28. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 May 17.
    View in: PubMed
    Score: 0.048
  29. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):414-421.
    View in: PubMed
    Score: 0.047
  30. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840.
    View in: PubMed
    Score: 0.045
  31. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.045
  32. Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Ann Oncol. 2017 Jun; 28 Suppl 3:iii137.
    View in: PubMed
    Score: 0.045
  33. Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). Ann Oncol. 2017 Jun; 28 Suppl 3:iii145-iii146.
    View in: PubMed
    Score: 0.045
  34. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Pract Radiat Oncol. 2017 Sep - Oct; 7(5):e291-e297.
    View in: PubMed
    Score: 0.044
  35. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):110-117.
    View in: PubMed
    Score: 0.044
  36. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.040
  37. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 12; 5(12):1271-81.
    View in: PubMed
    Score: 0.040
  38. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27.
    View in: PubMed
    Score: 0.039
  39. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7.
    View in: PubMed
    Score: 0.038
  40. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
    View in: PubMed
    Score: 0.036
  41. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer. 2014 Mar; 45(1):34-9.
    View in: PubMed
    Score: 0.036
  42. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90.
    View in: PubMed
    Score: 0.035
  43. Phase 1 study of N(1),N(11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1305-14.
    View in: PubMed
    Score: 0.035
  44. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8.
    View in: PubMed
    Score: 0.034
  45. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8.
    View in: PubMed
    Score: 0.032
  46. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e337-43.
    View in: PubMed
    Score: 0.031
  47. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012 Jun 15; 118(12):3026-35.
    View in: PubMed
    Score: 0.030
  48. A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20.
    View in: PubMed
    Score: 0.030
  49. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointest Cancer Res. 2011 Jul; 4(4):116-21.
    View in: PubMed
    Score: 0.030
  50. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102.
    View in: PubMed
    Score: 0.029
  51. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e735-41.
    View in: PubMed
    Score: 0.029
  52. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54.
    View in: PubMed
    Score: 0.026
  53. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
    View in: PubMed
    Score: 0.026
  54. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8.
    View in: PubMed
    Score: 0.025
  55. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92.
    View in: PubMed
    Score: 0.023
  56. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 01; 110(3):581-9.
    View in: PubMed
    Score: 0.023
  57. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13.
    View in: PubMed
    Score: 0.021
  58. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Apr 20; 24(12):1898-903.
    View in: PubMed
    Score: 0.021
  59. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.020
  60. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.